Amplia Therapeutics Ltd.ASX: ATX

Amplia Receives R&D Tax Rebate Totalling $4.78 Million

· Issued by Amplia Therapeutics Ltd. via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

This rebate is linked to the company's expenditures on research and development activities related to its FAK inhibitors, particularly narmafotinib, which is currently undergoing clinical trials for advanced pancreatic cancer. The funds will support ongoing clinical trials and additional research activities associated with narmafotinib.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/amplia-receives-randd-tax-rebate-totalling-dollar4.78-million

Release

22 OCTOBER 2026 ASX RELEASE AMPLIA RECEIVES R&D TAX REBATE TOTALLING $4.78 MILLION Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to advise that it has received A$4,778,235.52 via the Research and Development Tax Incentive from the...

Amplia Therapeutics Ltd. on 6ix

Story so far

Earlier from Amplia Therapeutics

Later from Amplia Therapeutics

All Amplia Therapeutics news releases